Gouty Arthritis of the Knee - Symptoms, Causes, Treatment & Prevention

```html

Overview

Gouty arthritis of the knee is a form of inflammatory arthritis caused by the deposition of monosodium urate crystals in the joint space. While gout most commonly involves the big toe (the first metatarsophalangeal joint), the knee is the second‑most frequently affected joint, accounting for 10–20% of acute gout attacks [1][2].

Gout results from chronic hyperuricemia—elevated serum uric acid (UA) levels—due either to increased production, decreased renal excretion, or a combination of both. When the solubility limit of uric acid is exceeded, crystals form and trigger an intense immune response, leading to pain, swelling, and redness.

Who is affected?

• Men are 3–4 times more likely than women to develop gout; the average age of onset is 40–50 years in men and 60–70 years in women after menopause.
• Approximately 8.3 million adults in the United States (3.9% of the population) have gout; about one‑third of these patients experience knee involvement at some point in their disease course [3].
• Risk is higher in people of Pacific Islander, Asian, and African descent, and in those with a family history of gout.

Symptoms

Symptoms of gouty arthritis of the knee can appear suddenly (often at night) and progress over hours to days. The classic picture includes:

• Severe pain: Intense, throbbing or burning pain that may make weight‑bearing impossible.
• Rapid onset: Pain usually reaches its peak within 12–24 hours.
• Swelling and effusion: The knee becomes visibly enlarged due to fluid accumulation.
• Redness and warmth: The overlying skin may appear pink or red and feel hot to the touch.
• Limited range of motion: Flexion and extension become painful; patients often avoid moving the joint.
• Joint stiffness: Persistent stiffness can last for weeks after the acute pain subsides.
• Tophi formation (chronic phase): Nodular deposits of urate crystals under the skin near the knee, which may become visible or palpable after years of uncontrolled hyperuricemia.
• Systemic symptoms: Low‑grade fever, chills, and malaise may accompany a severe attack.

Causes and Risk Factors

Underlying Pathophysiology

Gout arises when serum uric acid exceeds its saturation point (~6.8 mg/dL at 37 °C). Crystals precipitate in synovial fluid, triggering the NLRP3 inflammasome and release of interleukin‑1β, a powerful cytokine that drives inflammation.

Major Risk Factors

• Hyperuricemia: Persistent UA ≥ 7 mg/dL in men or ≥ 6 mg/dL in women.
• Dietary triggers: High intake of purine‑rich foods (red meat, organ meats, seafood), fructose‑sweetened beverages, and alcohol (especially beer and spirits).
• Obesity: Each 5 kg increase in BMI raises gout risk by ~20% [4].
• Renal insufficiency: Impaired uric acid excretion; CKD stages 3–5 markedly increase gout prevalence.
• Medications: Diuretics (thiazides, loop), low‑dose aspirin, cyclosporine, and some chemotherapy agents.
• Genetic predisposition: Polymorphisms in genes such as SLC2A9 and ABCG2 affect urate transport.
• Metabolic syndrome: Hypertension, dyslipidemia, and insulin resistance are strongly associated with hyperuricemia.
• Recent surgery or trauma to the knee: Can precipitate an acute gout flare.

Diagnosis

Accurate diagnosis combines clinical evaluation with laboratory and imaging studies.

Clinical Assessment

1. History: Sudden onset, severe pain, preceding dietary/alcohol triggers, prior gout attacks, medication use.
2. Physical exam: Warm, erythematous knee with effusion; tenderness to palpation, especially over the suprapatellar pouch.

Laboratory Tests

• Serum uric acid: Elevated in ~80% of acute gout cases, but a normal level does not rule it out.
• Synovial fluid analysis (gold standard): Arthrocentesis reveals cloudy fluid with needle‑shaped, negatively birefringent monosodium urate crystals under polarized light microscopy.
• Inflammatory markers: Elevated ESR and CRP support an inflammatory process but are non‑specific.

Imaging

• Plain radiographs: May be normal early; chronic gout can show “punched‑out” erosions with overhanging edges (rat‑bite lesions).
• Ultrasound: Demonstrates the “double contour” sign (urate crystal deposition on cartilage) and can guide joint aspiration.
• Dual‑energy CT (DECT): Allows specific visualization of urate crystals and differentiates them from calcium deposits.

Treatment Options

Treatment aims to relieve the acute flare, prevent recurrence, and address underlying hyperuricemia.

Acute Attack Management

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): Indomethacin 50 mg PO q6h, naproxen 500 mg PO q12h, or ibuprofen 400–600 mg PO q6–8h. Contraindicated in severe CKD, peptic ulcer disease, or cardiovascular disease.
• Colchicine: 1.2 mg PO then 0.6 mg 1 hour later (loading dose), followed by 0.6 mg BID as needed. Dose reduction is required for eGFR < 30 mL/min/1.73 m².
• Corticosteroids: Prednisone 30–40 mg PO daily tapering over 1–2 weeks, or intra‑articular methylprednisolone 40 mg if NSAIDs/colchicine are unsuitable.
• Joint aspiration & drainage: Reduces intra‑articular pressure, improves pain, and provides fluid for crystal analysis.

Urates‑Lowering Therapy (ULT)

Started after the acute flare has subsided (typically 2–4 weeks) to achieve a target serum uric acid < 6 mg/dL (or < 5 mg/dL if tophi are present).

• Allopurinol: First‑line xanthine oxidase inhibitor, 100 mg PO daily, titrated up to 300–600 mg based on uric acid levels and renal function.
• Febuxostat: 40 mg PO daily, increased to 80 mg if needed; useful in patients with mild–moderate CKD.
• Probenecid: Urate reabsorption inhibitor, 250 mg PO BID; contraindicated in gouty nephropathy and significant renal impairment.
• Lesinurad: Often combined with a xanthine oxidase inhibitor; 200 mg PO daily.
• Pegloticase (intravenous): Considered for refractory chronic gout; administered 8 mg IV every 2 weeks.

Lifestyle & Non‑pharmacologic Measures

• Dietary modification: Limit purine‑rich foods, reduce fructose intake, avoid alcohol (especially beer).
• Hydration: Aim for >2 L of water daily to facilitate renal uric acid excretion.
• Weight management: Gradual loss of 5–10% body weight can lower serum UA by 0.5–1 mg/dL.
• Physical therapy: Gentle range‑of‑motion exercises after the acute phase to preserve knee function.

Surgical/Procedural Options (Rare)

• Arthroscopy: Debridement of crystal deposits or removal of large tophi causing mechanical blockage.
• Knee replacement (Total Knee Arthroplasty): Considered for end‑stage joint damage secondary to chronic gouty arthritis.

Living with Gouty Arthritis of the Knee

Managing a chronic condition requires daily habits that reduce flare risk and preserve joint health.

• Medication adherence: Take urate‑lowering drugs exactly as prescribed, even when you feel well.
• Track triggers: Keep a food and symptom diary to identify specific foods or drinks that precipitate attacks.
• Regular monitoring: Check serum uric acid every 2–3 months until target is reached, then semi‑annually.
• Exercise safely: Low‑impact activities such as swimming, cycling, or walking help maintain knee mobility without overloading the joint.
• Cold/heat therapy: Apply ice packs (15 min) during an acute flare to reduce swelling; use warm compresses later for stiffness.
• Footwear: Choose supportive shoes with good shock absorption to lower stress on the knee during walking.
• Weight‑bearing aids: A cane or walker can off‑load the knee during painful periods.

Prevention

Primary prevention focuses on maintaining serum uric acid within the target range and avoiding known precipitants.

1. Dietary control:
   • Consume 0–4 oz of lean protein per day; prefer poultry, low‑fat dairy, and plant‑based proteins.
   • Eat plenty of cherries, berries, and vitamin C‑rich foods (they may modestly lower UA).
   • Limit sugary drinks; replace with water, herbal tea, or low‑fat milk.
2. Alcohol moderation: No more than 1 drink per day for women, 2 for men; avoid binge drinking.
3. Hydration: Aim for urine that is pale yellow; avoid dehydration during hot weather or intense exercise.
4. Weight management: A BMI < 25 kg/m² reduces gout risk.
5. Medication review: Discuss with your clinician the necessity of diuretics or low‑dose aspirin; consider alternatives when feasible.
6. Regular health check‑ups: Annual labs for serum uric acid, renal function, and lipid profile, especially if you have metabolic syndrome.

Complications

If untreated or poorly controlled, gouty arthritis of the knee can lead to:

• Chronic joint damage: Erosive arthritis with irreversible cartilage loss.
• Tophi formation: Large crystal deposits that may ulcerate or become infected.
• Secondary osteoarthritis: Accelerated wear of the knee joint, increasing the need for joint replacement.
• Renal stones: Urate crystals can precipitate in the urinary tract, causing nephrolithiasis.
• Cardiovascular disease: Hyperuricemia is independently associated with hypertension, coronary artery disease, and stroke [5].

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Gout.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/gout/symptoms-causes/syc-20372897
2. Khanna D, et al. “2020 American College of Rheumatology Guideline for the Management of Gout.” *Arthritis Care & Research*. 2020;72(6):772-795. DOI:10.1002/acr.23925
3. Centers for Disease Control and Prevention. “Prevalence of Gout and Hyperuricemia in the United States.” 2022. https://www.cdc.gov/nchs/fastats/gout.htm
4. Zhang Y, et al. “Association Between Obesity and Gout: A Systematic Review and Meta‑analysis.” *Rheumatology*. 2021;60(9):4265‑4275. DOI:10.1093/rheumatology/keab223
5. NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Gout Fact Sheet.” 2023. https://www.niams.nih.gov/health-topics/gout

```